Compare CNXN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | FTRE |
|---|---|---|
| Founded | 1982 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1998 | N/A |
| Metric | CNXN | FTRE |
|---|---|---|
| Price | $58.55 | $17.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.56 |
| AVG Volume (30 Days) | 80.6K | ★ 1.3M |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $2,878,704,000.00 | $2,759,900,000.00 |
| Revenue This Year | $5.85 | $3.17 |
| Revenue Next Year | $4.52 | $0.11 |
| P/E Ratio | $18.02 | ★ N/A |
| Revenue Growth | ★ 3.19 | 1.88 |
| 52 Week Low | $54.97 | $3.97 |
| 52 Week High | $74.84 | $19.53 |
| Indicator | CNXN | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 66.77 |
| Support Level | $56.53 | $16.91 |
| Resistance Level | $58.95 | $18.26 |
| Average True Range (ATR) | 1.25 | 0.89 |
| MACD | -0.11 | -0.18 |
| Stochastic Oscillator | 44.93 | 56.62 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.